Cargando…
Sodium Butyrate Effectiveness in Children and Adolescents with Newly Diagnosed Inflammatory Bowel Diseases—Randomized Placebo-Controlled Multicenter Trial
Background: Butyric acid’s effectiveness has not yet been assessed in the pediatric inflammatory bowel disease (IBD) population. This study aimed to evaluate the effectiveness of oral sodium butyrate as an add-on to standard therapy in children and adolescents with newly diagnosed IBD. Methods: This...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414716/ https://www.ncbi.nlm.nih.gov/pubmed/36014789 http://dx.doi.org/10.3390/nu14163283 |
_version_ | 1784776056408899584 |
---|---|
author | Pietrzak, Anna Banasiuk, Marcin Szczepanik, Mariusz Borys-Iwanicka, Agnieszka Pytrus, Tomasz Walkowiak, Jarosław Banaszkiewicz, Aleksandra |
author_facet | Pietrzak, Anna Banasiuk, Marcin Szczepanik, Mariusz Borys-Iwanicka, Agnieszka Pytrus, Tomasz Walkowiak, Jarosław Banaszkiewicz, Aleksandra |
author_sort | Pietrzak, Anna |
collection | PubMed |
description | Background: Butyric acid’s effectiveness has not yet been assessed in the pediatric inflammatory bowel disease (IBD) population. This study aimed to evaluate the effectiveness of oral sodium butyrate as an add-on to standard therapy in children and adolescents with newly diagnosed IBD. Methods: This was a prospective, randomized, placebo-controlled multicenter study. Patients aged 6–18 years with colonic Crohn’s disease or ulcerative colitis, who received standard therapy depending on the disease’s severity, were randomized to receive 150 mg sodium butyrate twice a day (group A) or placebo (group B). The primary outcome was the difference in disease activity and fecal calprotectin concentration between the two study groups measured at 12 weeks of the study. Results: In total, 72 patients with initially active disease completed the study, 29 patients in group A and 43 in group B. At week 12 of the study, the majority of patients achieved remission. No difference in remission rate or median disease activity was found between the two groups (p = 0.37 and 0.31, respectively). None of the patients reported adverse events. Conclusions: A 12-week supplementation with sodium butyrate, as adjunctive therapy, did not show efficacy in newly diagnosed children and adolescents with IBD. |
format | Online Article Text |
id | pubmed-9414716 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94147162022-08-27 Sodium Butyrate Effectiveness in Children and Adolescents with Newly Diagnosed Inflammatory Bowel Diseases—Randomized Placebo-Controlled Multicenter Trial Pietrzak, Anna Banasiuk, Marcin Szczepanik, Mariusz Borys-Iwanicka, Agnieszka Pytrus, Tomasz Walkowiak, Jarosław Banaszkiewicz, Aleksandra Nutrients Article Background: Butyric acid’s effectiveness has not yet been assessed in the pediatric inflammatory bowel disease (IBD) population. This study aimed to evaluate the effectiveness of oral sodium butyrate as an add-on to standard therapy in children and adolescents with newly diagnosed IBD. Methods: This was a prospective, randomized, placebo-controlled multicenter study. Patients aged 6–18 years with colonic Crohn’s disease or ulcerative colitis, who received standard therapy depending on the disease’s severity, were randomized to receive 150 mg sodium butyrate twice a day (group A) or placebo (group B). The primary outcome was the difference in disease activity and fecal calprotectin concentration between the two study groups measured at 12 weeks of the study. Results: In total, 72 patients with initially active disease completed the study, 29 patients in group A and 43 in group B. At week 12 of the study, the majority of patients achieved remission. No difference in remission rate or median disease activity was found between the two groups (p = 0.37 and 0.31, respectively). None of the patients reported adverse events. Conclusions: A 12-week supplementation with sodium butyrate, as adjunctive therapy, did not show efficacy in newly diagnosed children and adolescents with IBD. MDPI 2022-08-11 /pmc/articles/PMC9414716/ /pubmed/36014789 http://dx.doi.org/10.3390/nu14163283 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Pietrzak, Anna Banasiuk, Marcin Szczepanik, Mariusz Borys-Iwanicka, Agnieszka Pytrus, Tomasz Walkowiak, Jarosław Banaszkiewicz, Aleksandra Sodium Butyrate Effectiveness in Children and Adolescents with Newly Diagnosed Inflammatory Bowel Diseases—Randomized Placebo-Controlled Multicenter Trial |
title | Sodium Butyrate Effectiveness in Children and Adolescents with Newly Diagnosed Inflammatory Bowel Diseases—Randomized Placebo-Controlled Multicenter Trial |
title_full | Sodium Butyrate Effectiveness in Children and Adolescents with Newly Diagnosed Inflammatory Bowel Diseases—Randomized Placebo-Controlled Multicenter Trial |
title_fullStr | Sodium Butyrate Effectiveness in Children and Adolescents with Newly Diagnosed Inflammatory Bowel Diseases—Randomized Placebo-Controlled Multicenter Trial |
title_full_unstemmed | Sodium Butyrate Effectiveness in Children and Adolescents with Newly Diagnosed Inflammatory Bowel Diseases—Randomized Placebo-Controlled Multicenter Trial |
title_short | Sodium Butyrate Effectiveness in Children and Adolescents with Newly Diagnosed Inflammatory Bowel Diseases—Randomized Placebo-Controlled Multicenter Trial |
title_sort | sodium butyrate effectiveness in children and adolescents with newly diagnosed inflammatory bowel diseases—randomized placebo-controlled multicenter trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414716/ https://www.ncbi.nlm.nih.gov/pubmed/36014789 http://dx.doi.org/10.3390/nu14163283 |
work_keys_str_mv | AT pietrzakanna sodiumbutyrateeffectivenessinchildrenandadolescentswithnewlydiagnosedinflammatoryboweldiseasesrandomizedplacebocontrolledmulticentertrial AT banasiukmarcin sodiumbutyrateeffectivenessinchildrenandadolescentswithnewlydiagnosedinflammatoryboweldiseasesrandomizedplacebocontrolledmulticentertrial AT szczepanikmariusz sodiumbutyrateeffectivenessinchildrenandadolescentswithnewlydiagnosedinflammatoryboweldiseasesrandomizedplacebocontrolledmulticentertrial AT borysiwanickaagnieszka sodiumbutyrateeffectivenessinchildrenandadolescentswithnewlydiagnosedinflammatoryboweldiseasesrandomizedplacebocontrolledmulticentertrial AT pytrustomasz sodiumbutyrateeffectivenessinchildrenandadolescentswithnewlydiagnosedinflammatoryboweldiseasesrandomizedplacebocontrolledmulticentertrial AT walkowiakjarosław sodiumbutyrateeffectivenessinchildrenandadolescentswithnewlydiagnosedinflammatoryboweldiseasesrandomizedplacebocontrolledmulticentertrial AT banaszkiewiczaleksandra sodiumbutyrateeffectivenessinchildrenandadolescentswithnewlydiagnosedinflammatoryboweldiseasesrandomizedplacebocontrolledmulticentertrial |